share_log

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A:并购重组委托声明
美股SEC公告 ·  2024/11/27 06:23

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals announced a virtual special meeting of stockholders scheduled for January 9, 2025, at 10:00 a.m. Eastern Time. The meeting will address several key proposals, including the approval of issuing up to 2,862,596 shares upon warrant exercise, 75,000,000 shares upon conversion of a Senior Secured Promissory Note with Nirland Limited, and 58,000,000 shares upon conversion of a Convertible Note with A.G.P./Alliance Global Partners.Additionally, stockholders will vote on amending the company's Certificate of Incorporation to increase authorized shares from 251,000,000 to 601,000,000. Only holders of record as of December 4, 2024, are entitled to vote. The meeting will be conducted entirely online, and stockholders are encouraged to vote in advance.The Board of Directors recommends voting in favor of all proposals. The outcomes of these approvals are crucial for the company's capital structure and future financing activities.
Conduit Pharmaceuticals announced a virtual special meeting of stockholders scheduled for January 9, 2025, at 10:00 a.m. Eastern Time. The meeting will address several key proposals, including the approval of issuing up to 2,862,596 shares upon warrant exercise, 75,000,000 shares upon conversion of a Senior Secured Promissory Note with Nirland Limited, and 58,000,000 shares upon conversion of a Convertible Note with A.G.P./Alliance Global Partners.Additionally, stockholders will vote on amending the company's Certificate of Incorporation to increase authorized shares from 251,000,000 to 601,000,000. Only holders of record as of December 4, 2024, are entitled to vote. The meeting will be conducted entirely online, and stockholders are encouraged to vote in advance.The Board of Directors recommends voting in favor of all proposals. The outcomes of these approvals are crucial for the company's capital structure and future financing activities.
Conduit Pharmicals宣布了定于美国东部时间2025年1月9日上午10点举行的虚拟股东特别会议。会议将讨论几项关键提案,包括批准在行使认股权证时最多发行2,862,596股股票,在转换Nirland Limited的优先有担保本票后批准发行7500万股股票,以及在向A.G.P/Alliance Global Partners转换可转换票据后批准发行5800万股股票。此外,股东将就修改公司的公司注册证书进行投票,将授权股份从251,000,000股增加到6.01亿股。只有截至2024年12月4日的记录保持者才有权投票。会议将完全在线进行,鼓励股东提前投票。董事会建议对所有提案投赞成票。这些批准的结果对公司的资本结构和未来的融资活动至关重要。
Conduit Pharmicals宣布了定于美国东部时间2025年1月9日上午10点举行的虚拟股东特别会议。会议将讨论几项关键提案,包括批准在行使认股权证时最多发行2,862,596股股票,在转换Nirland Limited的优先有担保本票后批准发行7500万股股票,以及在向A.G.P/Alliance Global Partners转换可转换票据后批准发行5800万股股票。此外,股东将就修改公司的公司注册证书进行投票,将授权股份从251,000,000股增加到6.01亿股。只有截至2024年12月4日的记录保持者才有权投票。会议将完全在线进行,鼓励股东提前投票。董事会建议对所有提案投赞成票。这些批准的结果对公司的资本结构和未来的融资活动至关重要。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息